Trial characteristics were compared using the Pearson χ 2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. Statistical testing was 2-sided and performed using Stata/SE, version 14.2 (StataCorp) on complete data, with a significance level set at P < .05.
Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers
Survivors of Hodgkin lymphoma (HL) have a high risk of developing a subsequent breast cancer, particularly after chest irradiation.
1,2 Although breast cancer is a heterogeneous disease, the association between HL treatment and the estrogen receptor (ER) status of subsequent breast cancers has not been examined in large cohorts. We explored the association between radiotherapy for HL and risk of ER-positive and ER-negative breast cancer in a large, population-based cohort, accounting for chemotherapy. Results | The mean age at HL diagnosis was 26 years. Survivors were followed for a mean of 12 years (range, 5-38 years). In total, 377 invasive breast cancers were diagnosed (mean age, 45 years). Fifty-seven percent were ER positive, 34% were ER negative, and 9% had unknown/borderline ER status (Table) .
Compared with the general population, survivors of HL had a greater relative risk of ER-negative (SIR, 5.8; 95% CI, 4.8-6.9) than ER-positive breast cancer (SIR, 3.1; 95% CI,2.7-3.5; P < .001 for difference) ( Figure) . For ER-positive disease, the increased SIR was only observed among women who received radiotherapy (SIR, 3.9; 95% CI, 3.4-4.5). In this group, the SIR for ER-positive disease was lower in the chemotherapy than the no/unknown chemotherapy group (P = .04). In contrast, the SIRs for ER-negative breast cancer did not vary significantly by treatment.
Discussion | Breast cancer is a major source of morbidity in young HL survivors; cumulative risk estimates exceed 40% following high-dose mantle radiotherapy. 1 In the current study, radiotherapy was associated with an increased relative risk of ER-positive breast cancer, whereas the risk of ER-negative breast cancer was elevated irrespective of radiotherapy status. This suggests other mechanisms of increased risk for ER-negative cancers, such as genetic predisposition, and warrants further investigation especially given that ER-negative disease has poorer prognosis than ER-positive disease. A major strength of SEER-based studies is their large sample size and long-term, systematic follow-up. Nonetheless, lack of information on risk factors such as family history, reproductive factors, and hormone replacement therapy is a limitation as is the lack of detailed treatment information such as radiotherapy dose, fields, specific chemotherapeutic agents, and subsequent therapy. Ovarian exposure to radiotherapy and certain chemotherapeutic agents have been associated with reduced risks of subsequent breast cancer. [4] [5] [6] Despite changes in treatment recommendations, 40% of young women with HL currently receive radiotherapy, which was associated with an increased risk of ER-positive breast cancer in our study. Further investigation of the association between HL treatment and breast cancer subtype in studies with comprehensive treatment records will lead to a better 
Characteristics of Patients Using Patient Portals in Oncology
Nationwide, health care institutions have implemented electronic patient portals, providing patients real-time access to their health information and physicians. Portals have been studied extensively in primary care and certain specialty settings, but only recently has use in oncology been investigated. Longitudinal cancer care may be more intensive than many other specialties, resulting in increased portal data flow. 1 However, little is known about how patients access incoming portal data. In this study, we analyzed the likelihood of accessing portal data according to patient characteristics and type of portal content.
Methods | This study was reviewed and approved by the University of Texas Southwestern Medical Center institutional review board and a waiver of written informed consent was granted. We identified patients with a cancer diagnosis treated at the Harold C. Simmons Comprehensive Cancer Center who enrolled in the patient portal (MyChart) and received at least 1 laboratory and/or imaging result between January 1, 2007, and December 31, 2016. As described previously, 1 we extracted released results from Clarity databases, based on a MyChart timestamp by the data extraction cutoff (May 12, 2017). The primary endpoint was result viewing. Associations between patient characteristics and the odds of viewing results were tested using univariable and multivariable logistic regression models. Logistic regression models were run using the glm function in R statistical software (version 3.3.2, R Foundation). b Interpret with caution because chemotherapy is known to be underreported in SEER.
